| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 8e-10 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 7e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.26 | 7e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.19 | 4e-05 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0004 |